News on Pronova BioPharma and Par Pharmaceutical Inc. litigation

Pronova BioPharma (OSE: PRON) followed yesterday’s News on Pronova BioPharma and Teva Pharmaceuticals patent litigation with a similar announcement concerning ongoing litigation with another generic drug maker Par Pharmaceutical Inc. Pronova and Par ended the dispute concerning three patents and the court proceedings concerning Lovaza patents still continue in this case as well. The stock was unaffected by the news.